ITGR vs. EW: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2205153/itgr-vs-ew-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2205153
Jan 03, 2024 - ITGR vs. EW: Which Stock Is the Better Value Option?
0
Microbot Medical (MBOT) Announces Positive GLP Study Results
https://www.zacks.com/stock/news/2205065/microbot-medical-mbot-announces-positive-glp-study-results?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205065
Jan 03, 2024 - Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.
0
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now
https://www.zacks.com/stock/news/2204955/reasons-to-retain-shockwave-medical-swav-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2204955
Jan 03, 2024 - ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
0
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
https://www.zacks.com/stock/news/2202284/3-reasons-to-retain-nevro-nvro-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202284
Dec 26, 2023 - Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
0
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
https://www.zacks.com/stock/news/2202089/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202089
Dec 26, 2023 - PacBio's (PACB) product development activities raise optimism about the stock.
0
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
https://www.zacks.com/stock/news/2201457/here-s-why-you-should-retain-veeva-systems-veev-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2201457
Dec 22, 2023 - Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
0
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
https://www.zacks.com/stock/news/2201400/reasons-to-retain-cencora-cor-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2201400
Dec 22, 2023 - Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
0
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
https://www.zacks.com/stock/news/2200925/reasons-to-add-integer-holdings-itgr-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200925
Dec 21, 2023 - Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
0
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
https://www.zacks.com/stock/news/2200712/reasons-to-retain-fresenius-medical-fms-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200712
Dec 20, 2023 - Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
0
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
https://www.zacks.com/stock/news/2200160/glaukos-gkos-idose-tr-gets-fda-nod-for-glaucoma-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200160
Dec 19, 2023 - The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
0